Published peptide research references
AOD-9604
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Drugs@FDA: FDA-Approved Drugs database
U.S. Food and Drug Administration · 2026
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
Mazzarino M, Colpaert T, Deventer K, Van Eenoo P. · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM. · 2026
The World Anti-Doping Code International Standard: Prohibited List
World Anti-Doping Agency · 2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. · 2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA. · 2026
Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. · 2022
Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M. · 2016
Detection and in vitro metabolism of AOD9604.
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. · 2015
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Kwon DR, Park GY. · 2015
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Thevis M, Schänzer W. · 2014
Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Thevis M, Thomas A, Schänzer W. · 2014
Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.
Vanhee C, Moens G, Deconinck E, De Beer JO. · 2014
AOD-9604 does not influence the WADA hGH isoform immunoassay.
Orlovius AK, Thomas A, Schänzer W, Thevis M. · 2013
Current updates in the medical management of obesity.
Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, Goldman J. · 2012
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Zieba R. · 2007
Obesity drugs in clinical development.
Halford JC. · 2006
Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
Jensen MD. · 2006
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. · 2005
AOD-9604 Metabolic.
Wilding J. · 2004
Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR. · 2003
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. · 2003
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. · 2001
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. · 2001
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. · 2000